Shoshanna Goldin

UPDATE (5 MAY)

This working copy of the document Considerations for optimizing deployment of ChAdOx1-S [recombinant] vaccines in a time-limited constrained supply situation (AstraZeneca/AZD1222-Vaxzevria, AstraZeneca/SK Bioscience and SII/Covishield vaccines) provides an overview of the scientific basis and key programmatic considerations to guide national decision-making for countries on optimizing the deployment of AstraZeneca/AZD1222 and SII/Covishield vaccines under circumstances where vaccine supply is constrained, and future quantities and delivery dates cannot be reliably predicted.

Further details on the available evidence and key studies are available at the SAGE website, while resources for implementation and training are available at the COVID-19 vaccine introduction toolkit webpage.

UPDATE (5 MAY)

This working copy of the document Considerations for optimizing deployment of ChAdOx1-S [recombinant] vaccines in a time-limited constrained supply situation (AstraZeneca/AZD1222-Vaxzevria, AstraZeneca/SK Bioscience and SII/Covishield vaccines) provides an overview of the scientific basis and key programmatic considerations to guide national decision-making for countries on optimizing the deployment of AstraZeneca/AZD1222 and SII/Covishield vaccines under circumstances where vaccine supply is constrained, and future quantities and delivery dates cannot be reliably predicted.

Further details on the available evidence and key studies are available at the SAGE website, while resources for implementation and training are available at the COVID-19 vaccine introduction toolkit webpage.

The Access to COVID-19 Tools (ACT) Accelerator's Country Readiness and Delivery workstream  is developing COVID-19 vaccine specific training resources. 

COVID-19 vaccine explainers are designed to support countries in preparing for specific requirements presented by each vaccine product that receives WHO Emergency Use Listing (EUL) procedure and / or prequalification.

In addition, short instructional PowerPoints and videos are being developed that provide training on how to handle and use these COVID-19 vaccine product. You can share your comments, questions, and feedback by emailing [email protected] .

Resources are available here: https://www.who.int/tools/covid-19-vaccine-introduction-toolkit#Vaccine%20specific%20resources

UPDATE (5 MAY)

This working copy of the document Considerations for optimizing deployment of ChAdOx1-S [recombinant] vaccines in a time-limited constrained supply situation (AstraZeneca/AZD1222-Vaxzevria, AstraZeneca/SK Bioscience and SII/Covishield vaccines) provides an overview of the scientific basis and key programmatic considerations to guide national decision-making for countries on optimizing the deployment of AstraZeneca/AZD1222 and SII/Covishield vaccines under circumstances where vaccine supply is constrained, and future quantities and delivery dates cannot be reliably predicted.

Further details on the available evidence and key studies are available at the SAGE website, while resources for implementation and training are available at the COVID-19 vaccine introduction toolkit webpage.

This briefing note calls for the meticulous monitoring, recording, and reporting of COVID-19 vaccine doses, and distribution and consumption across all levels of the supply chain, including at service points. The need for a robust stock management system has been highlighted both in the Guidance on developing a national deployment and vaccination plan and COVID-19 vaccination: supply and logistics guidance.

This emphasizes the need to support and strengthen national systems, in order to prepare for: 1. Mitigation of supply chain and logistic risks, particularly those that are novel and/or heightened by the unique operational context of COVID-19 immunisation; and 2. Standardized COVAX reporting requirements, which are essential to securing timely and consistent additional vaccine supplies.

UPDATE (5 MAY)

This working copy of the document Considerations for optimizing deployment of ChAdOx1-S [recombinant] vaccines in a time-limited constrained supply situation (AstraZeneca/AZD1222-Vaxzevria, AstraZeneca/SK Bioscience and SII/Covishield vaccines) provides an overview of the scientific basis and key programmatic considerations to guide national decision-making for countries on optimizing the deployment of AstraZeneca/AZD1222 and SII/Covishield vaccines under circumstances where vaccine supply is constrained, and future quantities and delivery dates cannot be reliably predicted.

Further details on the available evidence and key studies are available at the SAGE website, while resources for implementation and training are available at the COVID-19 vaccine introduction toolkit webpage.

UPDATE (5 MAY)

This working copy of the document Considerations for optimizing deployment of ChAdOx1-S [recombinant] vaccines in a time-limited constrained supply situation (AstraZeneca/AZD1222-Vaxzevria, AstraZeneca/SK Bioscience and SII/Covishield vaccines) provides an overview of the scientific basis and key programmatic considerations to guide national decision-making for countries on optimizing the deployment of AstraZeneca/AZD1222 and SII/Covishield vaccines under circumstances where vaccine supply is constrained, and future quantities and delivery dates cannot be reliably predicted.

Further details on the available evidence and key studies are available at the SAGE website, while resources for implementation and training are available at the COVID-19 vaccine introduction toolkit webpage.

The Access to COVID-19 Tools (ACT) Accelerator's Country Readiness and Delivery workstream  is developing COVID-19 vaccine specific training resources. 

COVID-19 vaccine explainers are designed to support countries in preparing for specific requirements presented by each vaccine product that receives WHO Emergency Use Listing (EUL) procedure and / or prequalification.

In addition, short instructional PowerPoints and videos are being developed that provide training on how to handle and use these COVID-19 vaccine product. You can share your comments, questions, and feedback by emailing [email protected] .

Resources are available here: https://www.who.int/tools/covid-19-vaccine-introduction-toolkit#Vaccine%20specific%20resources

There are now two COVID-19 vaccine introduction courses available.

The Orientation to national deployment and vaccination planning for COVID-19 vaccines OpenWHO course is intended to help national and sub-national focal points in countries develop the NDVP and prepare for COVID-19 vaccine introduction: https://openwho.org/courses/covid-19-ndvp-en

The COVID-19 vaccination training for health workers OpenWHO course provides key information for how to ensure safe and efficient COVID-19 vaccine administration: https://openwho.org/courses/covid-19-vaccination-healthworkers-en

We are now in the process of developing short instructional videos and job aids that explain the specifics for each vaccine. For queries or feedback, please email: [email protected]